William Hearl, Ph.D., the founder of Immunomic Therapeutics Inc. (ITI), is an experienced and successful scientific businessman and entrepreneur. He worked closely with Dr. Tom August, Capital Genomix Inc., and Johns Hopkins University to capture the LAMP technology for ITI and begin operations in 2006. His extensive experience in intellectual property management and business development led to the speedy sub-license of the LAMP technology to Geron Corp. within 30 days of initiating operations.

William is also the founder of Capital Genomix Inc. (CGI), a Maryland-based biomarker and drug discovery company, having served as its first CEO from inception in 2000 until late 2002, when he assumed the role of chief scientific officer. William raised seed and Series A & B funding for CGI (~$5 million in cash/debt) and acquired the Dynex Technologies division of Thermo Scientific in a leveraged acquisition deal. (Dynex was subsequently divested yielding a tenfold return to the company.) He is also responsible for the acquisition and development of the core technologies of Capital Genomix: GeneSystem320™ was licensed exclusively from MD Anderson Cancer Center, and William was the inventor of the ImmunoMouse^™.

William has an established record of scientific productivity over his 20 years of work in the biotech industry. He started his career as a bench scientist at Electro-Nucleonics Inc. and developed blood-based diagnostics for HIV, HTLV-I, and Hepatitis C. He later worked at Life Technologies Corp. (now part of Invitrogen) and directed the Immunodetection Group. His lab developed a number of innovative antibody-based detection kits and reagents. He moved into scientific management when he became the director of R&D at Kirkegaard & Perry Laboratories Inc. in 1994.

William has a Ph.D. in Biochemistry from the University of Tennessee (Oak Ridge, Knoxville) and a BS from East Tennessee State University.